Notably, a significant decrease in KOR expression has been observed in the skin of CKD-aP patients (Wieczorek et al., 2020), indicating that KOR agonists may have therapeutic potential for CKD-aP treatment. Here, OPRK1 is linked to chronic kidney disease.